BBBporter™ Technology Platform

Online Inquiry

First Name *

Last Name *

Business Email *

Phone

Company/Institution

Job Title

Services of Interest *

When do you expect your project to start?

Project Description

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

BBB RMT Target Identification and Screening Services

Inquiry

Receptor-mediated transcytosis (RMT) is a key physiological mechanism that enables substances to cross the blood-brain barrier (BBB) selectively through receptor-ligand interactions. This process involves ligand binding to receptors on brain endothelial cells, followed by intracellular trafficking and release into the brain. Targeting RMT receptors has emerged as a promising strategy to enhance the delivery of biologics to the brain. While most research has focused on the transferrin receptor (TfR), the insulin receptor (IR), and the insulin-like growth factor 1 receptor (IGF1R), researchers are searching for novel RMT targets that offer characteristics such as brain specificity or regiospecificity within the brain. Selecting an appropriate receptor is essential for effective, specific brain drug delivery.

Novel approaches for identifying BBB RMT targets. — Fig. 1 New BBB RMT target identification methods. (Choi, *et al*., 2023)

Our Services

Ace Therapeutics offers comprehensive BBB RMT target identification and screening services. Our approach integrates molecular profiling or “omics” analyses with phenotypic screening approaches to help clients identify RMT receptors and screen RMT-targeting ligands. These services support the discovery of novel RMT targets, accelerating the development of drugs that can penetrate the brain for treating neurological diseases such as Alzheimer's disease, stroke, and multiple sclerosis.

RMT Receptor Identification and Validation Services

Services	Description
Novel RMT Receptor Identification Services	We specialize in identifying novel RMT receptors that are highly expressed in brain endothelial cells (BECs) and can mediate the delivery of cargos (e.g., protein or viral vector) across the BBB. Our platform integrates cutting-edge multi-omics, spatial profiling, and bioinformatics to discover specific RMT receptors with ideal properties.
RMT Receptor Characterization Services	We can use various approaches to characterize novel RMT receptors, including biological functions, expression in brain microvessels, BBB selectivity, receptor accessibility, and cross-species translatability.

RMT-Targeting Antibody or Peptide Screening Services

Our RMT-targeting ligand discovery approach involves the screening of peptide or antibody libraries displayed on phage or yeast. We aim to help clients identify RMT delivery ligands that can effectively bind to specific RMT receptors and traffic through BBB endothelial cells.

Services	Description
Target Selection	Known RMT receptors (e.g., TfR, IR, IGF1R, CD98hc, LRP1) Novel RMT receptors from multi-omics
Antibody or Peptide Generation and Expression	Phage and yeast display (10⁶-10¹⁰ variants) platforms Integration of human/murine sdAb, scFv, Fab, or IgG libraries Randomized, focused, cyclic, and stapled peptide libraries
Primary Screening	Affinity screening (ELISA, SPR, BLI) Cell binding/endocytosis (FACS, IF) Competition binding assay
In Vitro and In Vivo Screens	Various in vitro BBB models Screen for RMT-targeting peptide in rodents following intravenous injection

Our Advantages

Comprehensive Target Coverage

Expertise across validated (e.g., TfR, LDLR, IGF1R) and emerging (e.g., CD98hc, TMEM30A) RMT targets.

Diverse Screening Platforms

Integration of omics analysis with phenotypic screening strategies.

Professional and Experienced Team

Experienced team with deep expertise in BBB biology, RMT mechanisms, and brain drug delivery strategies.

Customized Project Execution

Tailored strategies from target discovery to BBB delivery validation.

At Ace Therapeutics, we are committed to helping clients identify BBB RMT targets that enable efficient and specific brain drug delivery. We strive to be your trusted partner in overcoming BBB drug delivery challenges. Contact us today to learn more about our RMT-based strategies for delivering drugs to the brain.

Reference

Choi, E. S., & Shusta, E. V. (2023). Strategies to identify, engineer, and validate antibodies targeting blood-brain barrier receptor-mediated transcytosis systems for CNS drug delivery. Expert Opinion on Drug Delivery, 20(12), 1789-1800.